Uganda vs Zimbabwe: HIV/AIDS deaths averted by antiretroviral therapy
Uganda
82,921 deaths
in 2024
Zimbabwe
84,960 deaths
in 2024
Uganda rank
6th
Zimbabwe rank
5th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Uganda
- Zimbabwe
How they compare
Zimbabwe currently reports 84,960 deaths against 82,921 deaths in Uganda, a difference of 2,039 deaths.
The two have swapped places 4 times across 35 shared years of data; in 1990 it was Zimbabwe ahead.
Uganda ranks 6th and Zimbabwe ranks 5th of 157 countries.
Across the 4 decades both report, Uganda averaged higher in 1 and Zimbabwe in 3.
Head to head by decade
| Decade | Uganda | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 275.56 deaths | 275.56 deaths | Zimbabwe |
| 2000s | 12,859 deaths | 11,375 deaths | 1,484 deaths | Uganda |
| 2010s | 56,072 deaths | 75,537 deaths | 19,465 deaths | Zimbabwe |
| 2020s | 81,329 deaths | 86,746 deaths | 5,418 deaths | Zimbabwe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Uganda or Zimbabwe?
- Zimbabwe, at 84,960 deaths against 82,921 deaths in Uganda as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Uganda and Zimbabwe?
- 2,039 deaths, with Zimbabwe ahead.
- How many years of comparable data are there for Uganda and Zimbabwe?
- 35 years are reported by both, from 1990 to 2024.
- How do Uganda and Zimbabwe rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Uganda ranks 6th and Zimbabwe ranks 5th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.